Homestead Advisers Corp Sells 91,000 Shares of Boston Scientific Corporation $BSX

Homestead Advisers Corp lowered its holdings in Boston Scientific Corporation (NYSE:BSX) by 12.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 668,426 shares of the medical equipment provider’s stock after selling 91,000 shares during the quarter. Homestead Advisers Corp’s holdings in Boston Scientific were worth $65,258,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of BSX. Steph & Co. bought a new stake in Boston Scientific during the third quarter valued at approximately $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. United Community Bank grew its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Finally, Kilter Group LLC bought a new position in Boston Scientific in the second quarter valued at $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several research analyst reports. Barclays dropped their price target on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday. Citigroup restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, January 14th. Stifel Nicolaus set a $110.00 price target on shares of Boston Scientific in a research report on Wednesday. Royal Bank Of Canada lifted their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Finally, Evercore ISI set a $112.00 price objective on shares of Boston Scientific in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $121.84.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat on both EPS and revenue; revenue grew ~15.9% year-over-year, and margins improved — the underlying quarter was strong, showing continued organic growth across several franchises. Boston Scientific announces results for fourth quarter and full year 2025
• Neutral Sentiment: Analyst coverage and the company’s earnings materials/earnings call provide detail for valuation and segment trends — useful for investors who want to dig into segment-level drivers and management’s assumptions. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Management’s FY‑2026 guidance was modestly below or roughly in line with Street expectations (FY EPS range and revenue range came in light enough to reset growth assumptions), and Q1 guidance was cautious — that outlook is the main driver of the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology (one of Boston Scientific’s higher-growth, higher-profile segments) underperformed vs. expectations, which worried investors about near-term growth momentum in a key franchise. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Unusually large put-option activity and heavy trading signaled short-term bearish positioning and hedging, amplifying downside pressure. BSX Earnings: Boston Scientific Stock Plunges on Weak Guidance
• Negative Sentiment: CEO insider selling (large block disclosed) adds to near-term negative sentiment even though insider transactions can be for many reasons. Insider sale SEC filing

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

NYSE:BSX opened at $75.50 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a fifty-two week low of $75.00 and a fifty-two week high of $109.50. The firm has a market cap of $111.92 billion, a PE ratio of 40.37, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67. The business has a 50 day moving average price of $94.37 and a 200-day moving average price of $99.13.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.